Friday, 24 April 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 24 April 2026
News

Lilly refuses PBS listing price

 Posted 24 April 2026

Despite finally winning a PBAC recommendation on its fourth gruelling attempt, Lilly has announced it will not make its blockbuster drug Mounjaro available on the PBS for Australians with type 2 diabetes after failing to secure a viable price.

The PBAC outcomes released this afternoon acknowledged the "clinical need for additional effective treatment options for people with type 2 diabetes" adding a PBS listing would improve equity of access to the drug.

To see the whole article, please login

Popular

Aussie pharma naughty or nice?
One of industry's best moves on
Final contender in MA Board race
MD's message to Dept workers
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home